MK-1045
Sponsors
Merck Sharp & Dohme LLC, MSD R&D (China) Co., Ltd.
Conditions
Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic LeukemiaCLL/SLLChronic Lymphocytic LeukaemiaFollicular LymphomaHematologic MalignanciesLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Phase 1
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
RecruitingNCT05579132
Start: 2022-11-01End: 2028-12-31Target: 203Updated: 2026-08-20
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
RecruitingNCT06189391
Start: 2021-03-16End: 2029-03-30Target: 100Updated: 2026-10-29
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
RecruitingNCT07363590
Start: 2026-02-19End: 2029-07-16Target: 21Updated: 2026-09-14
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RecruitingNCT07519772
Start: 2026-05-03End: 2031-04-01Target: 280Updated: 2026-10-29
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma
Not yet recruitingCTIS2025-523005-15-00
Target: 58Updated: 2026-05-29
Phase 2
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
RecruitingNCT07570173
Start: 2026-05-18End: 2033-10-18Target: 340Updated: 2026-10-19
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
RecruitingNCT07634471
Start: 2026-06-22End: 2035-07-23Target: 960Updated: 2026-10-26
A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.
Not yet recruitingCTIS2025-522777-10-00
Target: 2Updated: 2026-06-09
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Not yet recruitingCTIS2025-522267-15-00
Target: 36Updated: 2026-06-12
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Not yet recruitingNCT07709000
Start: 2026-10-09End: 2033-11-16Target: 60Updated: 2026-10-08
A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK- 1045 in Participants with Hematologic Malignancies
Not yet recruitingCTIS2025-522242-49-00
Target: 18Updated: 2026-10-16